OTC Rogaine Backed In USA

27 November 1995

Pharmacia & Upjohn's Rogaine Topical Solution 2% (minoxidil) has been backed for over-the-counter use by two US Food and Drug Administration advisory panels by men and women with common hereditary hair loss.

Minoxidil was first introduced in 1988 and remains the only approved hair loss treatment in the USA. It is marketed in more than 80 countries, and is approved for sale without a prescription in 12 countries, including the UK, Spain and the Netherlands. The OTC price will be one-third to one-half the cost of the prescription product, which costs $55-$60/month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight